Mangoceuticals, Inc.
MGRX- Exchange
- Nasdaq
- Industry
- Services-Misc Health & Allied Services, NEC
- SEC CIK
- 0001938046
No open-market purchases or sales by Mangoceuticals, Inc. insiders were filed in the last 90 days; 18 institutions reported holding it in 13F filings for Q2 2026, worth $455.6K in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Mangoceuticals, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 9
- −3 vs. Q3 2024
- Shares held
- 91.3K
- −1.18M (−92.8%) vs. Q3 2024
- Total value
- $220.9K
- −$78.0K (−26.1%) vs. Q3 2024
- New holders
- 4
- 1 more added
- Sold out
- 7
- 4 more reduced
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting MGRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 18 | $455.6K |
| Q1 2026 | 18 | $297.6K |
| Q4 2025 | 18 | $1.88M |
| Q3 2025 | 11 | $820.1K |
| Q2 2025 | 10 | $444.2K |
| Q1 2025 | 8 | $146.9K |
| Q4 2024 | 9 | $220.9K |
| Q3 2024 | 13 | $319.7K |
| Q2 2024 | 6 | $147.7K |
| Q1 2024 | 8 | $72.0K |
| Q4 2023 | 5 | $34.9K |
| Q3 2023 | 9 | $135.8K |
| Q2 2023 | 5 | $166.4K |
| Q1 2023 | 1 | $5.32K |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Mangoceuticals, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ackerman Capital Advisors, LLC | 34,500 | $83.5K | 0.02% | −838,856−96.0% | Reduced |
| Virtu Financial LLC | 20,501 | $50.0K | 0.00% | +1,662+8.8% | Added |
| HRT Financial LP | 13,472 | $32.0K | 0.00% | +13,472 | New |
| Geode Capital Management, LLC | 12,003 | $29.2K | 0.00% | −119,324−90.9% | Reduced |
| Federation des caisses Desjardins du Quebec | 4,600 | $11.1K | 0.00% | +4,600 | New |
| Tower Research Capital LLC (TRC) | 2,633 | $6.37K | 0.00% | +2,633 | New |
| Steward Partners Investment Advisory, LLC | 2,094 | $5.07K | 0.00% | −29,306−93.3% | Reduced |
| UBS Group AG | 1,524 | $3.69K | 0.00% | +1,524 | New |
| Bank of America Corp | 11 | $27 | 0.00% | −145−92.9% | Reduced |
| McCollum Christoferson Group LLC | 0 | $0 | 0.00% | −85,800−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −37,845−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −28,830−100.0% | Sold out |
| Creative Planning | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −17,077−100.0% | Sold out |
| StoneX Group Inc. | 0 | $0 | 0.00% | −13,647−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −10,187−100.0% | Sold out |
| PEAK6 Investments LLC | – | – | – | – | Not filed |